Welcome to LookChem.com Sign In|Join Free

CAS

  • or

168077-29-0

Post Buying Request

168077-29-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

168077-29-0 Usage

Description

1-(4-pyridinyl)piperidin-4-yl carbonyl chloride is a chemical compound characterized by the molecular formula C12H15ClN2O. It is a carbonyl chloride derivative featuring a piperidine ring with a 4-pyridinyl substituent, known for its high reactivity and utility in organic synthesis and pharmaceutical applications.

Uses

Used in Organic Synthesis:
1-(4-pyridinyl)piperidin-4-yl carbonyl chloride is used as a reagent for the acylation of amines and other nucleophiles, facilitating the formation of amides. Its high reactivity makes it a valuable component in synthetic chemistry.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(4-pyridinyl)piperidin-4-yl carbonyl chloride is utilized in the production of various pharmaceutical compounds, contributing to the development of new drugs and therapies.
Used in the Synthesis of Biologically Active Molecules:
1-(4-pyridinyl)piperidin-4-yl carbonyl chloride serves as a versatile building block for the synthesis of a wide range of biologically active molecules, further expanding its applications in the field of medicinal chemistry and drug discovery.

Check Digit Verification of cas no

The CAS Registry Mumber 168077-29-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,8,0,7 and 7 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 168077-29:
(8*1)+(7*6)+(6*8)+(5*0)+(4*7)+(3*7)+(2*2)+(1*9)=160
160 % 10 = 0
So 168077-29-0 is a valid CAS Registry Number.

168077-29-0Relevant articles and documents

NOVEL BENZAMIDINE COMPOUND

-

Page/Page column 32-33, (2008/06/13)

A novel compound, or a pharmaceutically acceptable salt thereof, represented by the formula (1) wherein the characters are as defined in the description. Thus, there can be provided an activated blood coagulation factor X inhibitor and a novel anti(blood)

Use of oxido-squalene cyclase inhibitors to lower blood cholesterol

-

, (2008/06/13)

PCT No. PCT/GB96/01985 Sec. 371 Date Feb. 13, 1998 Sec. 102(e) Date Feb. 13, 1998 PCT Filed Aug. 14, 1996 PCT Pub. No. WO97/06802 PCT Pub. Date Feb. 27, 1997A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein G, T1, T2 and T3 are selected from CH and N; provided that T2 and T3 are not both CH; A is selected from a direct bond and (1-4C)alkylene; X is selected from oxy, thio, sulphinyl, sulphonyl, carbonyl, carbonylamino, N-di-(1-6C)alkylcarbonylamino, sulphonamido, methylene, (1-4C)alkylmethylene and di-(1-6C)alkylmethylene, and when T2 is CH, X may also be selected from aminosulphonyl and oxycarbonyl; and Q is selected from (5-7C)cycloalkyl, a heterocyclic moiety containing up to 4 heteroatoms selected from nitrogen, oxygen and sulphur, phenyl, naphthyl, phenyl(1-4C)alkyl and phenyl(2-6C)alkenyl; for the manufacture of a medicament for treating diseases or medical conditions in which an inhibition of oxido-squalene cyclase is desirable.

A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase

Brown,Hollinshead,Stokes,Waterson,Clarke,Foubister,Glossop,McTaggart,Mirrlees,Smith,Wood

, p. 4964 - 4972 (2007/10/03)

A novel series of 4-piperidinopyridines and 4-piperidinopyrimidines showed potent and selective inhibition of rat 2,3-oxidosqualene cyclase-lanosterol synthase (OSC) (e.g. 26 IC50 rat = 398 ± 25 nM, human = 112 ± 25 nM) and gave selective oral inhibition of rat cholesterol biosynthesis (26 ED80 = 1.2 ± 0.3 mg/kg, n = 5; HMGCoA reductase inhibitor simvastatin ED80 = 1.2 ± 0.3 mg/kg, n = 5). The piperidinopyrimidine OSC inhibitors have a significantly lower pKa than the corresponding pyridine or the previously reported quinuclidine OSC inhibitor series. This indicates that other novel OSC inhibitors may be found in analogues of this series across a broader pKa range (6.0-9.0). These series may yield novel hypocholesterolemic agents for the treatment of cardiovascular disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 168077-29-0